The Global Automated Breast Ultrasound (ABUS) Market is witnessing a remarkable period of growth, driven by increasing awareness of breast cancer, advancements in imaging technology, and the rising demand for more accurate, non-invasive diagnostic tools. According to a comprehensive market intelligence report published by The Insight Partners, the Automated Breast Ultrasound Market is projected to grow from US$ 2.67 billion in 2024 to US$ 7.32 billion by 2031, registering a robust compound annual growth rate (CAGR) of 15.50% during the forecast period from 2025 to 2031.

What Is Automated Breast Ultrasound?

Automated Breast Ultrasound is an advanced medical imaging technology designed to improve breast cancer detection, particularly in women with dense breast tissue — a category where traditional mammography often falls short. Unlike handheld ultrasound, ABUS systems are automated, producing a standardized, reproducible 3D image of the entire breast. This makes the technology highly valuable for both radiologists and clinicians, improving consistency, accuracy, and workflow efficiency in clinical settings.

Key Market Segments

The report provides a detailed analysis across several critical segments:

By Product, the market is divided into Systems, Software, Accessories, and Services. Systems currently dominate, given their central role in performing automated scans, while software solutions — particularly AI-integrated platforms — are gaining significant momentum.

By Technology, the market is segmented into 2D and 3D imaging. 3D ABUS technology is increasingly preferred for its superior visualization of breast tissue architecture, enabling more precise identification of abnormalities.

By Application, screening holds the largest market share, as healthcare providers worldwide prioritize early detection programs. Diagnosis and research and clinical studies also represent growing application areas, particularly in academic and specialized medical centers.

By End User, hospitals account for a dominant share, supported by their access to large patient volumes and advanced diagnostic infrastructure. Diagnostic Imaging Centers and Ambulatory Surgical Centers are also key users, with the latter segment growing steadily as outpatient care models expand.

What's Fueling the Growth?

Several interrelated factors are propelling the ABUS market forward:

Rising breast cancer incidence remains a primary driver. Breast cancer is the most commonly diagnosed cancer among women globally, and early detection has been proven to significantly improve survival outcomes. ABUS systems offer a powerful complement to mammography, particularly for high-risk patients.

Technological innovation is reshaping the landscape. Integration of artificial intelligence and machine learning into ABUS platforms is helping reduce interpretation time, minimize human error, and enhance diagnostic accuracy. These innovations are encouraging greater adoption across healthcare facilities of varying sizes.

Growing awareness and screening programs — supported by government initiatives and non-profit campaigns — are boosting demand for effective breast imaging solutions, especially in emerging economies where breast cancer screening infrastructure has historically been limited.

Dense breast legislation in multiple countries and U.S. states has mandated that women be informed of dense breast tissue findings, creating a direct clinical pathway to supplemental imaging tools like ABUS.

Regional Insights

The market spans key geographies including North America, Europe, Asia-Pacific, South and Central America, and the Middle East and Africa. North America currently leads due to its advanced healthcare infrastructure and strong adoption of innovative diagnostic technologies. Asia-Pacific, however, is expected to register some of the fastest growth rates during the forecast period, driven by increasing healthcare expenditure, a growing middle-class population, and the expansion of cancer screening awareness campaigns in countries like China, India, and Japan.

Competitive Landscape

The report profiles several leading players shaping the ABUS market, including Siemens Healthcare, Koninklijke Philips N.V., General Electric Company, Hitachi Ltd., Canon Medical Systems, Delphinus Medical Technologies, and others. These companies are investing heavily in R&D, strategic partnerships, and regulatory approvals to expand their global footprint.

Outlook

With a strong CAGR of 15.50% and a market size poised to nearly triple by 2031, the Automated Breast Ultrasound market represents one of the most dynamic segments in medical imaging. Stakeholders — including technology manufacturers, investors, and healthcare providers — stand to benefit significantly by aligning their strategies with the prevailing trends in early detection, AI-driven diagnostics, and expanding access to women's health solutions worldwide.